perphenazine has been researched along with Dyskinesia, Drug-Induced in 30 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 74-year-old woman developed a slowly progressive hemichorea starting 3 weeks after discontinuation of low-dose amitriptyline and perphenazine." | 7.67 | A case of progressive hemichorea responsive to high-dose reserpine. ( Friedman, JH, 1986) |
| "A 74-year-old woman developed a slowly progressive hemichorea starting 3 weeks after discontinuation of low-dose amitriptyline and perphenazine." | 3.67 | A case of progressive hemichorea responsive to high-dose reserpine. ( Friedman, JH, 1986) |
| " Dopaminergic and serotonergic pathways are involved in the therapeutic and adverse effects of the drug." | 2.73 | Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients. ( Dahl, ML; Gunes, A; Jaanson, P; Scordo, MG, 2007) |
| "Perphenazine was not significantly different in overall effectiveness, compared with quetiapine, risperidone, and ziprasidone." | 2.73 | What CATIE found: results from the schizophrenia trial. ( Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Rosenheck, RA; Stroup, TS; Swartz, MS, 2008) |
| " This study demonstrates that PD is a safe and effective remedy for maintenance therapy in psychotic patients." | 2.66 | Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. ( Hansen, LB; Højholdt, K; Knudsen, P; Larsen, NE, 1985) |
| " We describe a case of acute dystonia with atypical onset without relation to changes in dosage and with laryngeal involvement with aphonia, but without dyspnoea." | 1.30 | [Atypical acute dystonia]. ( Mors, NP; Nielsen, AS, 1998) |
| "Haloperidol was implicated in 47 patients (37%), followed by amitriptyline/perphenazine in 30%, thioridazine in 27%, and chlorpromazine in 20%." | 1.28 | Neurologic approach to drug-induced movement disorders: a study of 125 patients. ( Jankovic, J; Miller, LG, 1990) |
| " Moreover pharmacokinetic data increasingly have been clinically applied." | 1.27 | Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985) |
| "It can sometimes be a cause of orofacial pain." | 1.27 | Tardive dyskinesia: an unrecognized cause of orofacial pain. ( Bassett, A; Blasberg, B; Remick, RA, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (46.67) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 9 (30.00) | 29.6817 |
| 2010's | 1 (3.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 1 |
| Gil-Ad, I | 2 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 1 |
| Geffen, Y | 1 |
| Weizman, A | 2 |
| Rephaeli, A | 1 |
| Khouzam, HR | 1 |
| Fusar-Poli, RR | 1 |
| Kraemer, HC | 1 |
| Glick, ID | 1 |
| Klein, DF | 1 |
| Haddad, P | 1 |
| Dursun, SM | 1 |
| Gunes, A | 1 |
| Scordo, MG | 1 |
| Jaanson, P | 1 |
| Dahl, ML | 1 |
| Kenney, C | 1 |
| Hunter, C | 1 |
| Davidson, A | 1 |
| Jankovic, J | 2 |
| Castrioto, A | 1 |
| Tambasco, N | 1 |
| Rossi, A | 1 |
| Calabresi, P | 1 |
| Swartz, MS | 1 |
| Stroup, TS | 1 |
| McEvoy, JP | 1 |
| Davis, SM | 1 |
| Rosenheck, RA | 1 |
| Keefe, RS | 1 |
| Hsiao, JK | 1 |
| Lieberman, JA | 1 |
| DeVeaugh-Geiss, J | 1 |
| Linnoila, M | 1 |
| George, L | 1 |
| Guthrie, S | 1 |
| Larsen, EB | 1 |
| Gerlach, J | 2 |
| Sweet, RA | 1 |
| Pollock, BG | 1 |
| Mulsant, BH | 1 |
| Rosen, J | 1 |
| Lo, KH | 1 |
| Yao, JK | 1 |
| Henteleff, RA | 1 |
| Mazumdar, S | 1 |
| Lauerma, H | 1 |
| Tuliharju, M | 1 |
| Mazure, CM | 1 |
| Nelson, JC | 1 |
| Jatlow, PI | 1 |
| Bowers, MB | 1 |
| Nielsen, AS | 1 |
| Mors, NP | 1 |
| Shtaif, B | 1 |
| Shiloh, R | 1 |
| Rosin, AJ | 1 |
| Fog, R | 1 |
| Pakkenberg, H | 1 |
| Juul, P | 1 |
| Bock, E | 1 |
| Jorgensen, OS | 1 |
| Andersen, J | 1 |
| Miller, LG | 1 |
| Knudsen, P | 3 |
| Galdi, J | 1 |
| Bonato, RR | 1 |
| Povlsen, UJ | 1 |
| Noring, U | 1 |
| Meidahl, B | 1 |
| Korsgaard, S | 1 |
| Waehrens, J | 1 |
| Sachdev, P | 1 |
| Bassett, A | 1 |
| Remick, RA | 1 |
| Blasberg, B | 1 |
| Sandyk, R | 1 |
| Consroe, PF | 1 |
| Iacono, RP | 1 |
| Hansen, LB | 2 |
| Højholdt, K | 2 |
| Larsen, NE | 2 |
| Friedman, JH | 1 |
2 reviews available for perphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Identification and management of tardive dyskinesia: A case series and literature review.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Clonazepam; Diagnosis, Differential; Dopamine Antagonists; Dysk | 2015 |
Clinical trials design lessons from the CATIE study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Dyskinesia, Dru | 2009 |
7 trials available for perphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dopamine Antagonists; Dyskinesia, Drug-Induced; Femal | 2007 |
What CATIE found: results from the schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dibenzothiaze | 2008 |
Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Behavior; Dyskinesia, Drug-Induced | 1997 |
Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Biperiden; Chlorprothixene; Dyskinesia, Drug-I | 1986 |
Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics.
Topics: Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Depressive Disorder; Double-Blind Me | 1988 |
[The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden].
Topics: Aged; Biperiden; Chlorprothixene; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Female; Halope | 1987 |
Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dysk | 1985 |
21 other studies available for perphenazine and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
Selecting antipsychotics in schizophrenia: lessons from CATIE.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Clinical Trials, Phase I as Topic; Dose-Respon | 2006 |
Metoclopramide, an increasingly recognized cause of tardive dyskinesia.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amitriptyline; Dyskinesia, Drug-Induced; Haloperidol; | 2008 |
Acute dystonia induced by the combination of midodrine and perphenazine.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Agonists; Antipsychotic Agents; Cytochrome P-450 CYP2D6; | 2008 |
Tardive Tourette syndrome.
Topics: Aged; Antipsychotic Agents; Chlorpromazine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Hum | 1980 |
Interaction between antidepressants and perphenazine in psychiatric inpatients.
Topics: Adult; Amitriptyline; Depressive Disorder; Dose-Response Relationship, Drug; Drug Interactions; Drug | 1982 |
Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Dyski | 1996 |
Neurological motor disorders experienced as religious phenomena: role of abnormal movement monitoring.
Topics: Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Perphenazine; Psychomotor Diso | 1998 |
Acute neuroleptic treatment in elderly patients without dementia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dose-Response R | 1998 |
[Atypical acute dystonia].
Topics: Acute Disease; Adult; Antipsychotic Agents; Aphonia; Dyskinesia, Drug-Induced; Dystonia; Humans; Mal | 1998 |
Evaluation of the neurotoxic activity of typical and atypical neuroleptics: relevance to iatrogenic extrapyramidal symptoms.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Cell Cycle; Cell Survival; Clozapine; | 2001 |
Treatment of dyskinetic and choreatic movement disorders in adults.
Topics: Adult; Aged; Athetosis; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskine | 1978 |
High-dose treatment of rats with perphenazine enanthate.
Topics: Animals; Basal Ganglia; Cell Count; Cerebral Cortex; Corpus Striatum; Dyskinesia, Drug-Induced; Nerv | 1976 |
Neurologic approach to drug-induced movement disorders: a study of 125 patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amitriptyline; Antipsychotic Agents; Chorea | 1990 |
Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
Topics: Administration, Oral; Antipsychotic Agents; Clopenthixol; Delayed-Action Preparations; Dose-Response | 1985 |
Combined antidepressant-antipsychotic drug preparations.
Topics: Amitriptyline; Drug Combinations; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Perphenazine | 1988 |
Tardive dyskinesia: an unrecognized cause of orofacial pain.
Topics: Dyskinesia, Drug-Induced; Facial Pain; Female; Humans; Methotrimeprazine; Middle Aged; Perphenazine | 1986 |
L-tryptophan in drug-induced movement disorders with insomnia.
Topics: Aged; Amitriptyline; Dyskinesia, Drug-Induced; Female; Humans; Perphenazine; Sleep Initiation and Ma | 1986 |
Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients.
Topics: Adult; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1985 |
A case of progressive hemichorea responsive to high-dose reserpine.
Topics: Aged; Amitriptyline; Chorea; Dyskinesia, Drug-Induced; Female; Humans; Perphenazine; Reserpine; Subs | 1986 |